Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC - Trial NCT06348927
Access comprehensive clinical trial information for NCT06348927 through Pure Global AI's free database. This Phase 2 trial is sponsored by Hunan Province Tumor Hospital and is currently Not yet recruiting. The study focuses on Non-Small Cell Lung Cancer. Target enrollment is 52 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Hunan Province Tumor Hospital
Timeline & Enrollment
Phase 2
Apr 30, 2024
Apr 30, 2027
Primary Outcome
Progression-free survival (PFS)
Summary
This is a phase II, open-label, single-arm, single-center clinical study to evaluate the
 preliminary efficacy of sunvozertinib in combination with anlotinib in patients with
 EGFR-sensitive mutations and co-mutations in locally advanced or metastatic treatment-naive
 non-small cell lung cancer.
 
 Condition or disease Intervention/treatment Phase Non-Small Cell Lung Cancer Drug:
 sunvozertinib Drug: anlotinib Phase 2
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06348927
Non-Device Trial